DSIP (5 mg)

At a Glance

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nine-amino-acid neuropeptide studied for its ability to promote deep delta-wave sleep and modulate the HPA axis. Published human research used intravenous administration; community researchers typically use subcutaneous injection at lower doses extrapolated from animal data.[1]

• Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2,500 mcg/mL) concentration.
• Standard dose: 200 mcg before sleep subcutaneous injection, 30–60 minutes prior to sleep.
• Easy measuring: At 2.5 mg/mL on a U-100 syringe, 1 unit = 0.01 mL = 25 mcg. A 200 mcg dose = 8 units / 0.08 mL.
• Doses per vial: 25 doses at 200 mcg standard; use within 4 weeks of reconstitution.
• Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.

Overview

• Goal: Promote deep delta-wave sleep via neuropeptide modulation of sleep architecture and HPA axis.[1]
• Schedule: Subcutaneous injection 30–60 minutes before sleep; 3–4 nights per week recommended.
• Dose: 100–300 mcg per injection (4–12 units / 0.04–0.12 mL); standard 200 mcg.
• Reconstitution: 2.0 mL BAC water per 5 mg vial → 2.5 mg/mL.
• Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

What You’ll Need

Plan based on a 30-day course at 200 mcg, 4 nights per week (approx. 17 injections, 3,400 mcg total).

• DSIP Vials (5 mg each): 3,400 mcg ÷ 5,000 mcg per vial → 1 vial (25 doses per vial at 200 mcg).
• Insulin Syringes (U-100, 1 mL): 1 per injection → 17 syringes for the course.
• Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle.
• Alcohol Swabs: 2 per injection → 34 swabs for the course.

How to Reconstitute

1. Allow frozen vial to reach room temperature (10–15 minutes).
2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
3. Inject slowly down the inner vial wall; do not inject directly onto the lyophilised cake.
4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
5. Label with reconstitution date; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Dosing Schedule

Reconstitute each 5 mg vial with 2.0 mL bacteriostatic water for a concentration of 2.5 mg/mL (1 unit on a U-100 syringe = 25 mcg). Administer subcutaneously 30–60 minutes before intended sleep time. Published human research documented cumulative benefit across 3–4 administrations; many researchers use DSIP 3–4 nights per week rather than nightly. DSIP is not intended for daytime use.[1]

Protocol Details

• Starting: 100 mcg (4 units / 0.04 mL) subcutaneous, 30–60 min before sleep for the first 5 nights.[2]
• Standard: 200 mcg (8 units / 0.08 mL) subcutaneous, 30–60 min before sleep.
• High: 300 mcg (12 units / 0.12 mL) subcutaneous, 30–60 min before sleep.
• Frequency: 3–4 nights per week; not required nightly.
• Injection site: Abdomen, thigh, or upper arm. Rotate sites between injections.
• Note: An initial mild arousal effect may occur in the first hour; sleep-promoting effects typically emerge in the second hour.[2]

Storage

• Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
• Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
• Appearance: Clear, colourless solution. Discard if cloudy, discoloured, or particulate.

How DSIP Works

DSIP is a nine-amino-acid neuropeptide (WAGGDASGE; MW 849 Da) first isolated from the cerebral venous blood of sleeping rabbits by Schoenenberger & Monnier at the University of Basel in 1977.[1] The most distinctive feature of DSIP — and its primary scientific puzzle — is that its receptor has never been identified despite nearly five decades of research.

What is established: DSIP crosses the blood-brain barrier via both passive diffusion and a saturable transport system. It modulates the hypothalamic-pituitary-adrenal (HPA) axis, correlating with cortisol levels. It interacts with the pineal gland through N-acetyltransferase modulation, influencing melatonin synthesis. Its antinociceptive effects in animals are blocked by the opioid antagonist naloxone, suggesting functional interaction with opioid receptors.[4] The net result of these interactions — in the correct dose and timing window — is an enhancement of delta-wave (slow-wave) EEG activity and deeper sleep architecture.

Good to Know

• Published human research used intravenous administration at 25 nmol/kg (≈1.5 mg IV for 70 kg). Community subcutaneous dosing at 100–300 mcg is extrapolated from animal research — no human pharmacokinetic data for SC DSIP exists.
• DSIP shows a U-shaped dose-response curve in animal models — both sub-optimal and supra-optimal doses may produce diminished or reversed effects. Start at the lower end and assess response over several nights before increasing.[3]
• Cumulative benefit was observed across multiple administrations in human IV studies; results on a single night may be modest.
• Do not use concurrently with opioid medications — DSIP has demonstrated opioid receptor activity and additive CNS/respiratory depression is theoretically possible.
• Athletes subject to anti-doping rules should seek written confirmation from their Anti-Doping Organization before use; WADA Section S2 catch-all clauses may apply.
• Sleep (human IV data): Weak but statistically significant improvements in sleep efficiency and onset latency in the only double-blind study (Bes et al. 1992, N=16); no subjective improvement was found.[2] Earlier open studies were more positive but less controlled.
• Withdrawal (uncontrolled human data): 87–97% of 107 inpatients showed marked improvement in alcohol or opiate withdrawal symptoms (Dick et al. 1984); no placebo group was included.[5]
• Pain (animal data): Supraspinal opioid-mediated analgesia confirmed in mice; no human analgesic trials exist.[4]
• Neuroprotection (animal data): Intranasal DSIP accelerated motor recovery post-stroke in rats; Deltaran combination achieved 100% ischemia survival vs. 62% in controls.
• First-hour arousal: An initial mildly arousing effect in the first hour post-injection is documented in human studies; do not expect immediate sedation.
• No daytime sedation reported in any published human study.
• For background on DSIP's mechanism, evidence, and safety profile, see What Is DSIP?.

Tips for Best Results

• Administer 30–60 minutes before the intended sleep time to align with the delayed onset of sleep-promoting effects.
• Minimize blue-light exposure and screen use in the 30–60 minutes post-injection to support the transition to sleep.
• Maintain a consistent sleep schedule — DSIP modulates natural sleep architecture and works best when circadian rhythms are regular.
• Start at 100 mcg and observe over 5 nights before increasing to 200 mcg; the U-shaped dose-response means more is not always better.
• Adequate dietary magnesium and consistent wind-down routines complement sleep peptide research protocols.

Injection Tips

• Clean the vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully before proceeding.
• Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose precisely.
• Pinch a fold of skin and insert the needle at 45° into subcutaneous fat (90° is acceptable with a short needle into a well-pinched fold).
• Inject slowly over 2–3 seconds; do not aspirate. Withdraw the needle, apply gentle pressure, and do not rub the site.
• Rotate injection sites (abdomen, thighs, upper arms) and dispose of each syringe in a sharps container immediately after use.